BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17706533)

  • 1. Granulomatous dermatitis: a rare pitfall in lymphoma staging with [
    Enke JS; Gäble A; Reitsam NG; Schaller T; Trepel M; Hirschbühl K; Welzel J; Dierks A; Kircher M; Lapa C
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3479-3480. PubMed ID: 37233786
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigation of dose minimisation protocol for 18F-FDG PET-CT in the management of lymphoma postchemotherapy followup.
    Sonoda LI; Sanghera B; Wong WL
    ScientificWorldJournal; 2012; 2012():208135. PubMed ID: 22545010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Schäfer JF
    Rofo; 2024 May; 196(5):422-423. PubMed ID: 38663378
    [No Abstract]   [Full Text] [Related]  

  • 4. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
    Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
    Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.
    Schiepers C; Dahlbom M
    Eur Radiol; 2011 Mar; 21(3):548-54. PubMed ID: 21174096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
    Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
    Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
    Bar-Shalom R
    Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.